Jci_page_head_homepage_01 Jci_page_head_homepage_02
Kazuichi Maruyama, Masaaki Ii, Claus Cursiefen, David G. Jackson, Hiroshi Keino, Minoru Tomita, Nico Van Rooijen, Hideya Takenaka, Patricia A. D’Amore, Joan Stein-Streilein, Douglas W. Losordo, J. Wayne Streilein
Published in Volume 115, Issue 9
J Clin Invest. 2005; 115(9):2363–2372 doi:10.1172/JCI23874
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 6

Characterization of PECs. (A) Flow cytometric analysis of thioglycollate-activated adherent PECs. Percentage of PECs positive for CD11b is shown. The x axis shows FITC fluorescence intensity. (B) RT-PCR of CD11b+ macrophages. Shown are CD11b macrophages stimulated with thioglycollate VEGFR-3 (lane 1), VEGFR-2 (lane 3), and VEGF-C (lane 5) and their unstimulated counterparts (lanes 2, 4, and 6, respectively). The far left lane provides size markers. (C) Multicolor FACS analysis of CD11b+ macrophages. Percentages of double-positive cells are shown. (DL) Immunocytochemistry of thioglycollate-activated adherent PECs. PE-conjugated CD11b (D) and FITC-visualized Prox-1 (E) staining. (F) Overlay of D and E showing dual expression. PE-conjugated CD11b (G) and FITC-visualized podoplanin (H) staining. (I) Overlay of G and H showing dual expression. PE-conjugated CD11b (J) and FITC-visualized LYVE-1 (K) staining; (L) overlay of J and K showing dual expression. Magnification, ×400.